Which routes can be used to administer alirocumab and evolocumab?

Alirocumab and evolocumab are both monoclonal antibodies used primarily for the treatment of high cholesterol levels, specifically in patients with hypercholesterolemia or those who cannot reach their cholesterol goals with statins alone. The preferred method of administration for these medications is subcutaneously.

Subcutaneous administration allows for easy self-injection by patients, providing convenience and flexibility compared to other routes. This method ensures that the medications are delivered into the fatty tissue just beneath the skin, where they can be absorbed into the bloodstream effectively.

In contrast, intravenous administration is not a common route for these drugs because they are formulated for subcutaneous use, which aids in their pharmacokinetics and patient adherence. Oral administration is also not viable for alirocumab and evolocumab, as they are not stable in the gastrointestinal tract and cannot be effectively absorbed if taken by mouth. Intramuscular injection is also not indicated for these medications, as their design as subcutaneous therapies means that this route would not provide the desired absorption profile.

Overall, the subcutaneous route is specifically chosen for these medications to optimize their efficacy and patient experience.